DEVELOPMENT TRENDS AND MORPHOLOGICAL CHARACTERISTICS OF PRECANCEROUS BREAST DISEASES IN WOMEN RESIDING IN THE ARAL SEA REGION
Ключевые слова:
breast canser, dyshormonal diseases, histological variants, masthopaty, dyshormonal hiperplaziaАннотация
Breast cancer (BC),- the most common cancer in women is considered. 1.5 million new cases are detected every year and this is 25% of all malignant tumors. The incidence is growing rapidly in European countries. Especially often this process develops against the background of dyshormonal processes, based on this, a retrospective analysis was carried out in order to identify the role of dyshormonal pathology in the development of precancerous diseases.
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. Adham A. Khodjaniyazov, Baxrom S. Yuldashev, Mekhriban Kh. Khadjimuratova// Pathomorphological Characteristics of Metastatic Breast Cancer in Women Living in the Lower Aral Sea Region- American Journal of Medicine and Medical Sciences 2026, 16(2): 448-452
2. Atakhanova N.E., Almuradova D.M. Results of comprehensive treatment of operable triple-negative breast cancer // Bulletin of the Association of Physicians of Uzbekistan. – Tashkent, 2018. – No. 1. – P. 48–53
3. Alexandrova L.M., Starinsky V.V., Kaprin A.D., et al. Prevention of oncological diseases as the basis for interaction between the oncology service and primary healthcare // Research and Practice in Medicine. – 2017. – Vol. 4, No. 1. – P. 74–80.
4. Yuldashev B.S., Khadjimuratova M.K. Immunohistochemical characteristics of breast fibroadenoma disease in women living in Aral Sea region // International Journal of Integrative and Modern Medicine. – 2024. – Vol. 2, No. 11. – P. 203–206. – DOI: 10.2995/5319
5. Kakharov A.Zh. 2019 Clinical, morphological and molecular genetic features in the diagnosis and treatment of breast cancer."
6. De Boever J., Verheugen C., Van Maele G., Vandekerckhove D. Steroid concentrations in serum, breast glandular tissue, and breast cyst fluid in control and progesterone-treated patients. Endocrinology of cystic breast disease. Ed. A. Angeli. New York: Raven Press, 1983. Rr. 93-9.
7. Zava D.T., Groves M.N., Stanchik F.Z. Percutaneous absorption of progesterone. Maturitas 2014, 77 (2): 91-2
8. Kogan I.Yu., Myasnikova M.O., Musina E.V. Progesterone in the treatment of mastopathy. Ed. E.K. Ailamazyan. SPb, 2012.68 p. (in Russian).
9. Vysotskaya I.V., et al. Endocrine-Sensitive Tumors of the Reproductive System: A Guide for Physicians. – Moscow: Specialized Medical Book Publishing House (SIMK), 2014. – 126 p.
10. Lyubchenko L.N. Genetic testing in hereditary breast cancer // Practical Oncology. – 2014. – Vol. 15, No. 3. – P. 107–117.
11. Kuligina E.Sh. Epidemiological and molecular aspects of breast cancer // Practical Oncology. – 2010. – Vol. 11. – P. 203–216.
12. Meskikh E.V., Rozhkova N.I. Application of Progestogel in diffuse forms of mastopathy // Tumors of the Female Reproductive System. – 2012. – No. 1. – P. 57.
13. Semiglazov V.F., Merabishvili B.M., Semiglazov V.V., et al. Epidemiology and screening of breast cancer // Problems in Oncology. – 2017. – Vol. 63, No. 3. – P. 375–384.
14. Jorgensen T.J., Helzlsouer K.J., Clipp S.C., et al. DNA repair gene variants associated with benign breast disease in high cancer risk women // Cancer Epidemiology, Biomarkers & Prevention. – 2009. – Vol. 18, No. 1. – P. 346–350.
